Skip to main content
Premium Trial:

Request an Annual Quote

Miller Named CFO at Cepheid, Vernier Joins Clinical Data's PGx Health Division, Scolnick Joins Alnylam's Board, and More

NEW YORK (GenomeWeb News) - Andrew Miller will step into the roles of senior VP and CFO at Cepheid in mid-April. Miller currently is VP and chief accounting officer at Autodesk, and before that he was senior VP and CFO at MarketFirst Software. Miller is taking over for John Sluis, who retired from Cepheid at the end of 2007.

The Nevada Biotechnology and Bioscience Consortium has given its inaugural Harry Reid Award for Biotechnology in Nevada to Senator Harry Reid (D-Nev.), for whom the award is named. The consortium’s president, John Laub, said the group was giving the award to Reid because he has “secured more than $100 million for Nevada universities” and because he has been a “leading supporter of higher education” in the state.

Clinical Data has named William Vernier to be VP of operations in the company’s PGxHealth division. Vernier formerly worked at Quest Diagnostics.

Gen-Probe COO Carl Hull will take on the additional title of president in March. Hull joined the company a year ago as executive VP and COO. Hull formerly was VP and GM of Applied Biosystems’ Sequence Detection System and Microarrays business, and he previously was involved in sales and marketing at Ventana Medical Systems and at Abbott Laboratories.

Znomics has retained James Posada as an advisor to help with business development of collaborative programs and of pharmaceutical and biotechnology partnering, and he will oversee technology in-licensing and out-licensing. Posada formerly was senior VP for business development at Glycofi, and he was a senior director for business development at Protein Design Labs.

Edward Scolnick has been appointed to Alnylam’s board of directors and its scientific advisory board. Scolnick formerly was an executive at Merck, a member of the US Food and Drug Administration’s Science Board, and he is currently on the board of directors at Millipore.

Wellgen has appointed Robert Hellauer to be CFO. Hellauer comes to the company after having a long career in finance in pharmaceutical, consumer, and telecommunications businesses, including working at Lucent Technologies and at Johnson & Johnson.

AdvanDX has appointed Else Beth Trautner to be VP of sales and marketing. Trautner formerly was executive VP at Dako, where she was involved in organizing and restructuring the company’s global operations.

Bard Geesaman will serve as executive director of life sciences for the X Prize Foundation. Geesaman founded two heathcare companies and he was a venture capitalist, the company said, and in this role he will be responsible for developing, funding, and managing new prizes in the life sciences field.

Perlegen announced three new hires this week, naming Kevin Cooksy to be VP of business development, Julie Brooks general counsel and corporate secretary, and Brenda Rogers to be VP of human resources. Cooksy previously was involved in corporate development at Agilent Technologies; Brooks served in a variety of legal and corporate management positions at healthcare technology companies including Westmark Intrenational and Access Health; and Rogers was a consultant to biotech companies and was VP of human resources at OneWorld Health.

Combimatrix Molecular Diagnostics has hired Kavita Reddy to be its laboratory director. Reddy formerly was senior director of Genzyme Genetics Manhattan,and she was an associate director and scientific director of Quest Diagnostics.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.